Weekly Research Analysts’ Ratings Changes for Merck & Co. (MRK)

Weekly Research Analysts’ Ratings Changes for Merck & Co. (MRK)

Merck & Co., Inc. (NYSE MRK) opened at 64.88 on Wednesday. Merck & Co., Inc. has a 52 week low of $55.10 and a 52 week high of $66.80. The firm has a market cap of $177.46 billion, a P/E ratio of 41.35 and a beta of 0.79. The company has a 50-day moving average of $63.35 and a 200 day moving average of $62.92.

A number of research firms have changed their ratings and price targets for Merck & Co. (NYSE: MRK):

Merck & Co. (NYSE:MRK) last announced its quarterly earnings data on Tuesday, May 2nd. The company reported $0.88 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.83 by $0.05. The firm had revenue of $9.43 billion during the quarter, compared to the consensus estimate of $9.25 billion. Merck & Co. had a return on equity of 24.08% and a net margin of 14.30%. The business’s revenue for the quarter was up 1.3% on a year-over-year basis. During the same period in the prior year, the business earned $0.89 EPS. On average, equities analysts predict that Merck & Co., Inc. will post $3.84 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, July 10th. Investors of record on Thursday, June 15th will be paid a $0.47 dividend. This represents a $1.88 annualized dividend and a yield of 2.90%. The ex-dividend date of this dividend is Tuesday, June 13th. Merck & Co.’s dividend payout ratio is currently 92.61%.

In related news, EVP Adam H. Schechter sold 53,850 shares of the stock in a transaction dated Monday, April 3rd. The stock was sold at an average price of $63.48, for a total value of $3,418,398.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director C Robert Kidder sold 5,000 shares of the stock in a transaction dated Friday, May 12th. The stock was sold at an average price of $63.54, for a total value of $317,700.00. Following the completion of the sale, the director now directly owns 14,317 shares of the company’s stock, valued at $909,702.18. The disclosure for this sale can be found here. 0.05% of the stock is currently owned by corporate insiders.

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “MRK”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Related posts

Leave a Comment